The drug is also being studied in other immune-mediated diseases – phase 3 trials of upadacitinib in atopic dermatitis, psoriatic arthritis, Crohn's disease, and ulcerative colitis are ongoing ...

and AbbVie's Rinvoq (upadacitinib) – which are currently waiting for FDA decisions on extending their use into atopic dermatitis. Pfizer's Xeljanz follow-up Cibinqo (abrocitinib) was approved ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...

Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

The following is a summary of “A year in review: new treatments and expanded indications in dermatology in 2024,” published in the January 2025 issue of Dermatology by McGrath et al. In 2024, ...

If the patient has reported a history of steroid use, the first treatment step should be to discontinue the medication's use immediately. However, the patient should be aware that this may result ...